Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products… Read more
Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Net Assets
Latest net assets as of September 2025: CN¥1.08 Billion CNY
Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has net assets worth CN¥1.08 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.84 Billion) and total liabilities (CN¥762.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.08 Billion |
| % of Total Assets | 58.65% |
| Annual Growth Rate | 17.17% |
| 5-Year Change | -21.53% |
| 10-Year Change | N/A |
| Growth Volatility | 51.37 |
Jiangsu Aidea Pharmaceutical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual net assets of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.07 Billion | -5.19% |
| 2023-12-31 | CN¥1.13 Billion | -6.12% |
| 2022-12-31 | CN¥1.20 Billion | -8.46% |
| 2021-12-31 | CN¥1.31 Billion | -3.68% |
| 2020-12-31 | CN¥1.36 Billion | +144.47% |
| 2019-12-31 | CN¥556.24 Million | +6.41% |
| 2018-12-31 | CN¥522.71 Million | +1.68% |
| 2017-12-31 | CN¥514.09 Million | +71.14% |
| 2016-12-31 | CN¥300.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Aidea Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1212.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥420.78 Million | 42.90% |
| Other Comprehensive Income | CN¥16.29 Million | 1.66% |
| Other Components | CN¥878.48 Million | 89.56% |
| Total Equity | CN¥980.89 Million | 100.00% |
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ral Yatirim Holding AS
IS:RALYH
|
$472.79 Million |
|
Peoples Fin
NASDAQ:PFIS
|
$472.90 Million |
|
Scientex Bhd
KLSE:4731
|
$472.96 Million |
|
Dakota Gold Corp.
NYSE MKT:DC
|
$472.97 Million |
|
Citycon Oyj
PINK:COYJF
|
$472.76 Million |
|
GULF KEYSTONE PETR.
F:GVP1
|
$472.73 Million |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
$472.69 Million |
|
HEARTLAND GRP HLDGS
F:73X
|
$472.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Aidea Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,125,538,212 to 980,894,898, a change of -144,643,314 (-12.9%).
- Net loss of 138,835,090 reduced equity.
- Dividend payments of 15,852,126 reduced retained earnings.
- Other comprehensive income decreased equity by 3,439,020.
- Other factors increased equity by 13,482,922.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-138.84 Million | -14.15% |
| Dividends Paid | CN¥15.85 Million | -1.62% |
| Other Comprehensive Income | CN¥-3.44 Million | -0.35% |
| Other Changes | CN¥13.48 Million | +1.37% |
| Total Change | CN¥- | -12.85% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Aidea Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.95x to 6.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.80 | CN¥16.03 | x |
| 2017-12-31 | CN¥1.38 | CN¥16.03 | x |
| 2018-12-31 | CN¥1.40 | CN¥16.03 | x |
| 2019-12-31 | CN¥1.32 | CN¥16.03 | x |
| 2020-12-31 | CN¥3.24 | CN¥16.03 | x |
| 2021-12-31 | CN¥3.12 | CN¥16.03 | x |
| 2022-12-31 | CN¥2.85 | CN¥16.03 | x |
| 2023-12-31 | CN¥2.66 | CN¥16.03 | x |
| 2024-12-31 | CN¥2.34 | CN¥16.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Aidea Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.23%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.91x
- Recent ROE (-14.15%) is below the historical average (-2.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 4.74% | 5.52% | 0.58x | 1.48x | CN¥-15.80 Million |
| 2017 | -7.39% | -27.88% | 0.21x | 1.28x | CN¥-89.40 Million |
| 2018 | 1.65% | 3.11% | 0.39x | 1.36x | CN¥-43.65 Million |
| 2019 | 6.05% | 9.75% | 0.44x | 1.40x | CN¥-21.97 Million |
| 2020 | 2.92% | 13.76% | 0.20x | 1.06x | CN¥-96.21 Million |
| 2021 | -2.29% | -11.73% | 0.18x | 1.10x | CN¥-160.97 Million |
| 2022 | -10.36% | -50.86% | 0.15x | 1.38x | CN¥-244.10 Million |
| 2023 | -6.76% | -18.49% | 0.24x | 1.55x | CN¥-188.62 Million |
| 2024 | -14.15% | -33.23% | 0.22x | 1.91x | CN¥-236.92 Million |
Industry Comparison
This section compares Jiangsu Aidea Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Co Ltd (688488) | CN¥1.08 Billion | 4.74% | 0.71x | $472.78 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |